The results of the analysis, shown in Figure 3 , showed a notable trend towards a decrease in DAS28 (ESR and CRP) starting at week 4 after initiation of treatment with the investigational drug.
← all excerpts
Efficacy, safety and immunogenicity of the biosimilar etanercept compared to the reference formulation original etanercept in patients with rheumatoid arthritis: An open-label, randomized, comparative, multicenter study.
1
—
—